CD274 and neoplasm: Though the U.S. FDA has approved three anti-PD-L1 antibody clones for clinical diagnosis in lung cancer, including 28-8, 22C3 and SP142 clones; the PD-L1 proportion score of SP142 was an outlier compared with 28-8, 22C3 and E1L3N clones on both tumor and immune cells in 90 lung cancer patients [27].